Pancreatic Cancer Research

ResearcherUniversity of UdineActive in the last 2 years

Giuseppe Aprile

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2007-4077; OpenAlex author ID A5017740245, A5083057852, A5090671983. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
71
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 18

  1. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  2. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  3. Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer. Co-author DOI 10.2217/fon-2023-0137↗
  4. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Last author DOI 10.3390/cancers15030900↗
  5. The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. First author DOI 10.1038/s41598-022-12214-4↗
  6. Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. Co-author DOI 10.1159/000524868↗
  7. Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer. First author DOI 10.2174/1389201023666220307090450↗
  8. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. Co-author DOI 10.1002/jcsm.12368↗
  9. Sarcopenia: looking to muscle mass to better manage pancreatic cancer patients. Last author DOI 10.1097/spc.0000000000000455↗
  10. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2017.01.015↗
  11. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Co-author DOI 10.1016/j.critrevonc.2017.03.025↗
  12. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Co-author DOI 10.18632/oncotarget.4492↗
  13. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. Co-author DOI 10.3748/wjg.v21.i41.11793↗
  14. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Co-author DOI 10.1038/bjc.2014.494↗
  15. Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s13277-012-0520-2↗
  16. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Co-author DOI 10.1016/j.ejca.2013.06.041↗
  17. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Co-author DOI 10.1245/s10434-011-2205-2↗
  18. Treatment trends in metastatic pancreatic cancer patients: Is it time to change? Co-author DOI 10.1016/j.dld.2010.09.010↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Monica Ramello · 4 shared papers, 2022–2023 · strength 0.74
  2. Roberto Petrioli · 4 shared papers, 2022–2023 · strength 0.74
  3. Giandomenico Roviello · 4 shared papers, 2022–2023 · strength 0.74
  4. Martina Catalano · 4 shared papers, 2022–2023 · strength 0.74
  5. Mario Scartozzi · 4 shared papers, 2017–2026 · strength 0.46
  6. Enrico Vasile · 3 shared papers, 2017–2026 · strength 0.41
  7. Debora Basile · 3 shared papers, 2019–2023 · strength 0.36
  8. Caterina Vivaldi · 2 shared papers, 2023–2026 · strength 0.35
  9. Davide Melisi · 2 shared papers, 2017–2026 · strength 0.26
  10. Francesca Bergamo · 2 shared papers, 2013–2026 · strength 0.23
  11. Valentina Fanotto · 2 shared papers, 2019–2023 · strength 0.22
  12. Francesco Leone · 2 shared papers, 2017–2023 · strength 0.21
  13. Michele Reni · 6 shared papers, 2011–2017 · strength 0.21
  14. Chiara Carmen Miceli · 1 shared paper, 2026 · strength 0.20
  15. Letizia Procaccio · 1 shared paper, 2026 · strength 0.20
  16. Federico Nichetti · 1 shared paper, 2026 · strength 0.20
  17. Andrea Pretta · 1 shared paper, 2026 · strength 0.20
  18. Simona Casalino · 1 shared paper, 2026 · strength 0.20
  19. Elisa Giommoni · 1 shared paper, 2026 · strength 0.20
  20. Mariacristina Di Marco · 1 shared paper, 2026 · strength 0.20
  21. Sara Lonardi · 1 shared paper, 2026 · strength 0.20
  22. Ferdinando De Vita · 1 shared paper, 2026 · strength 0.20
  23. Guido Giordano · 1 shared paper, 2026 · strength 0.20
  24. Matteo Landriscina · 1 shared paper, 2026 · strength 0.20
  25. Roberto Bianco · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.